Home / Pharmaceuticals / Alzheimer’s Therapeutic Market By Drug Type (Memantine Hydrochloride, Donepezil Hydrochloride, Rivastigmine, Galantamine Hydrobromide) - Growth, Share, Opportunities & Competitive Analysis, 2015 - 2022

Alzheimer’s Therapeutic Market By Drug Type (Memantine Hydrochloride, Donepezil Hydrochloride, Rivastigmine, Galantamine Hydrobromide) - Growth, Share, Opportunities & Competitive Analysis, 2015 - 2022

Published: May 2016 | Report Code: 57811-05-16

This report on global Alzheimer’s therapeutics market studies various drugs used for treatment of Alzheimer’s along with pipeline analysis of upcoming potential drugs. According to Institute of Health Metrics and Evaluation, Alzheimer’s is one of the most common diseases that cause dementia, which leads to a loss of cognitive abilities, including reasoning, thinking, and remembering. Alzheimer’s is an irreversible, progressive brain disease that eventually destroys the ability to carry out the most basic tasks of daily living. While treatments to manage symptoms are available, Alzheimer’s has no cure. Thus, drug pipeline of Alzheimer’s treatment market comprises potential drugs which are more target specific and posses innovative properties. 

For the purpose of this study, the various drugs studied include memantine hydrochloride donepezil hydrochloride rivastigmine and galantamine hydrobromide. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

Alzeimer's Therapeutic Market

The pipeline analysis for Alzheimer’s therapeutics market comprises projected market sales of Phase III drugs estimated till 2022. The phase III drugs included in the pipeline analysis are ENA713 (Novartis Pharmaceuticals), Flutemetamol (18F) (GE Healthcare), LY450139 (Eli Lilly and Company), Dimebon (Medivation, Inc. & Pfizer, Inc.), and Aripiprazole/ BMS-337039 (Otsuka Pharmaceutical, Inc.). The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.

The geographic segmentation of the global Alzheimer’s therapeutics market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Global Alzheimer’s Therapeutics Market Portaiture
2.2 Global Alzheimer’s Therapeutics Treament Market, by Drugs, 2015 (USD Mn)
2.3 Relativity Analysis: Global Alzheimer’s Therapeutics Market, by Geography, 2015 & 2022 (USD Mn)

Chapter 3 Alzheimer’s Therapeutics Market: Market Dynamics and Outlook
3.1 Alzheimer’s Therapeutics Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Alzheimer’s Therapeutics Market, 2015 (Value %)

Chapter 4 Global Alzheimer’s Therapeutics Market, By Drugs
4.1 Preface
4.2 Memantine Hydrochloride
4.3 Donepezil Hydrochloride
4.4 Rivastigmine
4.5 Galantamine Hydrobromide
4.6 Pipeline Analysis
4.6.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.6.1.1 ENA713
4.6.1.2 Flutemetamol (18F)
4.6.1.3 LY450139
4.6.1.4 Dimebon
4.6.1.5 Aripiprazole/ BMS-337039
4.6.2 Tabular Representation of Phase II and I Drugs

Chapter 5 Global Alzheimer’s Therapeutics Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Rest of the World (RoW)
5.5.1 Latin America
5.5.2 Middle East and Africa

Chapter 6 Company Profiles
6.1 Pfizer Inc.
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
6.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Novartis International AG
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 Axovant Sciences Ltd.
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
6.3.4 News Coverage
6.4 Acadia Pharmaceuticals, Inc.
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Portfolio
6.4.4 News Coverage
6.5 Biotie Therapies
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Portfolio
6.5.4 News Coverage
6.6 Astra Zeneca plc
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product portfolio
6.6.4 News Coverage
6.7 Eli Lilly, Inc.
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Portfolio
6.7.4 News Coverage
6.8 F. Hoffman Le Roche
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Portfolio
6.8.4 News Coverage
6.9 Merck & Co.
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Portfolio
6.9.4 News Coverage
6.10 H. Lundbeck A/S
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage
6.11 Takeda Pharmaceutical Company Ltd.
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage

List Of Table :

TABLE 1 Global Alzheimer’s Therapeutics Market Revenue, by Drugs, 2013 – 2022 (USD Mn)
TABLE 2 Global Alzheimer’s Therapeutics Marrket Revenue, by Geography, 2013 – 2022 (USD Mn)
TABLE 3 North America Alzheimer’s Therapeutics Market Revenue, by Country, 2013 – 2022 (USD Mn)
TABLE 4 Europe Alzheimer’s Therapeutics Market Revenue, by Country, 2013 – 2022 (USD Mn)
TABLE 5 Asia - Pacific Alzheimer’s Therapeutics Market Revenue, by Country, 2013 – 2022 (USD Mn)
TABLE 6 Rest of the World Alzheimer’s Therapeutics Market Revenue, by Region, 2013 – 2022 (USD Mn)

List Of Figure :

FIG. 1 Global Alzheimer’s Therapeutics Market, by Drugs, 2015 (USD Mn)
FIG. 2 Relativity Analysis: Global Alzheimer’s Therapeutics Market, by Geography, 2015 & 2022 (USD Mn)
FIG. 3 Attractive Investment Proposition, Global Alzheimer’s Therapeutics Market, 2015
FIG. 4 Market Share Analysis: Global Alzheimer’s Therapeutics Market, 2015 (Value %)
FIG. 5 Global Memantine Hydrochloride Market for Alzheimer’s Treatment, 2013 – 2022 (USD Mn)
FIG. 6 Global Donepezil Hydrochloride Market for Alzheimer’s Treatment, 20137– 2022 (USD Mn)
FIG. 7 Global Rivastigmine Market for Alzheimer’s Treatment, 2013 –2022 (USD Mn)
FIG. 8 Global Galantamine Hydrobromide Market for Alzheimer’s Treatment, 2013 – 2022 (USD Mn)
FIG 9 Pipeline Analysis: Global ENA713 Market for Alzheimer’s Therapeutics, Upto 2022 (USD Mn)
FIG 10 Pipeline Analysis: Global Flutemetamol (18F) Market for Alzheimer’s Therapeutics, Upto 2022 (USD Mn)
FIG 11 Pipeline Analysis: Global LY450139 Market for Alzheimer’s Therapeutics, Upto 2022 (USD Mn)
FIG 12 Pipeline Analysis: Global Dimebon Market for Alzheimer’s Therapeutics, Upto 2022 (USD Mn)
FIG 13 Pipeline Analysis: Global Aripiprazole (BMS-337039) Market for Alzheimer's Therapeutics, Upto 2022 (USD Mn)
FIG 14 Global U.S. Alzheimer’s Therapeutics Market Revenue, 2013 – 2022 (USD Mn)
FIG 15 Global Canada Alzheimer’s Therapeutics Market Revenue, 2013 – 2022 (USD Mn)
FIG 16 Global U.K Alzheimer’s Therapeutics Market Revenue, 2013 – 2022 (USD Mn)
FIG. 17 Global Germany Alzheimer’s Therapeutics Market Revenue, 2013 – 2022 (USD Mn)
FIG. 18 Global Rest of Europe Alzheimer’s Therapeutics Market Revenue, 2013 – 2022 (USD Mn)
FIG. 19 Global China Alzheimer’s Therapeutics Market Revenue, 2013 – 2022 (USD Mn)
FIG. 20 Global Japan Alzheimer’s Therapeutics Market Revenue, 2013 – 2022 (USD Mn)
FIG. 21 Global Rest of Asia Pacific Alzheimer’s Therapeutics Market Revenue, 2013 – 2022 (USD Mn)
FIG. 22 Global Latin America Alzheimer’s Therapeutics Market Revenue, 2013 – 2022 (USD Mn)
FIG. 23 Global Middle East and Africa Alzheimer’s Therapeutics Market Revenue, 2013 – 2022 (USD Mn)

According to Alzheimer’s Society, there are no drug treatments that can cure Alzheimer's disease or any other common type of dementia. However, medicines have been developed for Alzheimer's disease that can temporarily alleviate symptoms, or slow down their progression, in some cases. There are two types of drug classes used in treatment of Alzheimer’s disease, acetylcholinesterase (ACE) inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonist. Based on the drug type, the Alzheimer’s therapeutics market is segmented into:

  • Memantine Hydrochloride
  • Donepezil Hydrochloride
  • Rivastigmine
  • Galantamine Hydrobromide

Alzeimer's Therapeutic Market

According to press release published by BioArctic Neuroscience AB, the Alzheimer’s disease is age-related and the number of patients doubles every five years beyond age 65, meaning that 30% of 85-year-olds are suffering from the disease. Current estimates indicate 35.6 million people worldwide are affected and researchers estimate that this number could triple by 2050. According to medical practitioners, donepezil, rivastigmine or galantamine is offered as part of treatment for patients with mild-to-moderate Alzheimer's disease. However, use of memantine is for severe Alzheimer's disease and most of the medical practitioners recommend memantine for people with moderate Alzheimer's disease who cannot take the cholinesterase inhibitor drugs. The current market dynamics suggest that drugs currently available in the market are expected to lose their exclusivity during the forecast period. Hence, the current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies

Pipeline Analysis

According to Alzheimer’s Society, there are no drug treatments that can cure Alzheimer's disease or any other common type of dementia. However, medicines have been developed for Alzheimer's disease that can temporarily alleviate symptoms, or slow down their progression, in some cases. There are two types of drug classes used in treatment of Alzheimer’s disease, acetylcholinesterase (ACE) inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonist. Based on the drug type, the Alzheimer’s therapeutics market is segmented into:

  • Phase III Drugs:
    • ENA713 (Novartis Pharmaceuticals)
    • Flutemetamol (18F) (GE Healthcare)
    • LY450139 (Eli Lilly and Company)
    • Dimebon (Medivation, Inc. & Pfizer, Inc.)
    • Aripiprazole (BMS-337039) (Otsuka Pharmaceutical, Inc.)
  • Phase II Drugs:
    • florbetapir 18F (Avid Radiopharmaceuticals)
    • MK0249 (Merck Sharp & Dohme Corp.)
    • Biological: ACC-001 3 μg (Pfizer, Inc.)
    • Biological: ACC-001 10 μg (Pfizer, Inc.)
    • Biological: ACC-001 + QS-21 (Pfizer, Inc.)
    • ELND005 (Scyllo-inositol) (Transition Therapeutics Ireland Limited)
    • EGb761 (Ipsen)
    • CHF 5074 (CERESPIR)
  • Phase I Drugs:
    • Biological: V950 (Merck Sharp & Dohme Corp.)

According to Alzheimer’s Association, if no novel treatments are found to prevent, delay or stop the progression of Alzheimer’s disease, the number of people affected in the U.S. is expected to soar to 15 million by 2050 and the cost of care for Alzheimer’s patients could increase five-fold to $1.2 trillion a year. The drugs currently available in Alzheimer’s therapeutics market treat the cognitive symptoms of the disease such as memory loss, confusion and problems with thinking but do not address the underlying causes of the disease. However, ongoing research on Alzheimer’s treatment is focused on treatments that may restrain or slow down disease progression disease modifying agents. Other areas of research are concentrating at the role inflammation and insulin resistance developed in Alzheimer’s disease. According to market experts the major challenges in Alzheimer’s clinical trials are as follows:

  • Recruitment and retention of clinical trial participants
  • Acquiring the essential augmented funding for clinical trials (federal and private both)
  • Collecting informed consent from patients who are suffering from the effects of the disease
  • Involving caregivers in research trials because they can actually add an extra burden to their daily routine

For the purpose of this study, the global Alzheimer’s therapeutics market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Alzeimer's Therapeutic

North America was observed as the largest market for Alzheimer’s treatment in the base year 2015. According to Alzheimer’s Association, an estimated 5.2 million Americans of all ages have Alzheimer’s disease in 2014. This includes an estimated 5 million people aged 65 and older; approximately 200,000 individuals under age 65 who have younger-onset Alzheimer’s. The key factors driving North America Alzheimer’s therapeutics market are rise in prevalence of geriatric based diseases, aging population, high adoption of novel treatments and rising public awareness related to diagnosis of age-specific diseases. According to a study published by Institute for Health Metric and Evaluation, in 2013 Alzheimer’s and other dementias were responsible for about 3% of all deaths globally. In several countries, however, it caused more than 10% of all deaths in 2013: Finland (13%), Italy (11.4%), Iceland (10.9%), Switzerland (10.8%), Canada (10.8%), and the US (10.5%). Apart of higher-income countries middle-income countries in Southeast Asia, Eastern Europe, the Middle East, and elsewhere carry an increasingly large burden of Alzheimer’s deaths. In 2013, Indonesia, Ukraine, Mexico, Poland, Turkey, Vietnam, Thailand, Argentina, Pakistan, Bangladesh, and Iran had more than 10,000 deaths from Alzheimer’s. Thus, globally Alzheimer’s market is expected to grow significantly throughout the forecast period 2016 – 2022.  

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients